TG Therapeutics Inc (TGTX)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Inventory turnover | 3.44 | — | — | — | — |
| Receivables turnover | 4.33 | — | 4.82 | — | — |
| Payables turnover | — | — | — | — | — |
| Working capital turnover | 0.84 | 0.02 | 0.03 | 0.00 | 0.00 |
TG Therapeutics Inc's inventory turnover ratio for December 31, 2023, is 3.44, indicating that the company is selling its inventory approximately 3.44 times during the year. However, data for previous years is not available for comparison.
The receivables turnover ratio for December 31, 2023, is 4.33, showing that the company collects its accounts receivable approximately 4.33 times during the year. In comparison to December 31, 2021, the receivables turnover has decreased from 4.82 to 4.33, which indicates a slight decline in efficiency in collecting receivables.
Data for payables turnover is not provided, so it is not possible to analyze the company's usage of accounts payable effectively.
The working capital turnover ratio for December 31, 2023, is 0.84, showing that the company generates $0.84 in net sales for every dollar of working capital employed. The significant increase in the working capital turnover ratio from 0.02 in December 31, 2022, to 0.84 in December 31, 2023, indicates the company's improved efficiency in utilizing its working capital to generate sales. This suggests better liquidity management and potentially improved operational performance.
Average number of days
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 106.22 | — | — | — | — |
| Days of sales outstanding (DSO) | days | 84.37 | — | 75.79 | — | — |
| Number of days of payables | days | — | — | — | — | — |
Days of Inventory on Hand (DOH):
- In 2023, TG Therapeutics Inc had 106.22 days of inventory on hand, indicating that the company takes more than three months to sell its inventory. This could imply inefficiencies in inventory management or a slow-moving product line.
- No data is available for the previous years, so it's challenging to assess the trend in inventory turnover over time.
Days of Sales Outstanding (DSO):
- For 2023, the company had a DSO of 84.37 days, which suggests that it takes approximately three months to collect payments from its customers. This could signify a longer accounts receivable collection period, potentially impacting cash flow.
- In 2021, the DSO was 75.79 days, indicating a slight increase in the collection period in 2023 compared to 2021.
Number of Days of Payables:
- Data is missing for all years, which makes it impossible to evaluate the company's payment practices and its relationship with suppliers.
- Without information on payables turnover, it is challenging to gauge the efficiency of the company's payables management strategy over the years.
Long-term
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Fixed asset turnover | 2,326.81 | 9.07 | 11.15 | 0.32 | 0.54 |
| Total asset turnover | 0.67 | 0.01 | 0.02 | 0.00 | 0.00 |
TG Therapeutics Inc's long-term activity ratios demonstrate significant fluctuations over the past five years. The fixed asset turnover ratio has shown a volatile pattern, ranging from 0.32 in 2020 to a high of 2,326.81 in 2023. This suggests that the company has been able to generate substantial sales relative to its investment in fixed assets in recent years, indicating an efficient utilization of these assets.
On the other hand, the total asset turnover ratio has been consistently low, generally below 1, over the same period. This indicates that the company has struggled to generate sales in relation to its total assets. The ratio improved slightly from 0.00 in 2019 and 2020 to 0.67 in 2023, but it still remains relatively low.
Overall, the fixed asset turnover ratio suggests that TG Therapeutics Inc has been able to efficiently leverage its fixed assets to generate revenue in the more recent years. However, the low total asset turnover ratio indicates that the company may need to focus on improving its overall asset utilization to enhance its financial performance going forward.